Like the Zodiac cipher before it cracked, RNF43 has spent years giving cancer geneticists just enough clues to be annoying.
The suspect: a gene called RNF43, which helps keep a growth signal called Wnt from turning the colon lining into a construction site with no permits. Wnt is useful when your body needs cells to grow, repair, or behave like civilized citizens. But when the brakes fail, cells can start multiplying like they just found an unlimited buffet coupon.
In this new Gut paper, Palles and colleagues walked into the evidence room with a big question: are inherited RNF43 mutations and tumor-acquired RNF43 mutations doing the same dirty work in colorectal cancer, or are we looking at two different culprits wearing the same trench coat?
Exhibit A: The Gene With Two Alibis
First, a quick field note. Germline mutations are the ones you are born with. They are in every cell, like a family heirloom nobody asked for. Somatic mutations show up later, inside the tumor itself, after life, biology, and bad cellular decisions have had time to improvise.
RNF43 has been linked to serrated polyposis syndrome, where people develop multiple serrated polyps in the colon. “Serrated” means the tissue can look saw-toothed under the microscope, which is a charmingly carpentry-themed way to describe a cancer warning sign. These polyps can sometimes become colorectal cancer.
The old story went something like this: inherited RNF43 loss-of-function mutation equals lots of serrated polyps and higher colorectal cancer risk. Case closed. Somebody dim the lights.
Except biology hates tidy endings.
The Detectives Bring a Bigger Net
This study did something useful: it stopped relying only on dramatic families with strong cancer histories and looked across much larger, more ordinary datasets. The team studied 49,823 colorectal cancer and/or polyp cases from CORGI, the 100,000 Genomes Project, and UK Biobank, plus 165,250 controls. They also analyzed 2,722 colorectal cancers for somatic mutations.
That is not a magnifying glass. That is a searchlight.
They did find the classic smoking gun: a germline RNF43 loss-of-function variant, p.Thr158ProfsTer6, in a multigenerational family with early-onset colorectal cancer and serrated or filiform polyps. Very noir. Very “the butler has suspicious fingerprints.”
But then the plot swerved. In the larger population datasets, 23 cases and 47 controls carried germline RNF43 mutations. Many cases did not have lots of polyps. Many did not have a dramatic family history. Sometimes the colorectal cancer appeared to develop independently of the inherited RNF43 mutation.
That last bit matters. It means an RNF43 mutation can be present at the scene without necessarily committing the crime. Cancer genetics, apparently, includes loitering.
Location, Location, Mutation
The sharpest clue was where the mutation landed in the gene.
Overall, germline RNF43 variants were associated with colorectal cancer risk, with an odds ratio of about 2.7. That suggests increased risk, but not the sky-high “everyone panic politely” risk seen with some classic hereditary cancer syndromes.
Then the investigators split the gene into regions. N-terminal germline mutations looked more risky. C-terminal germline mutations did not show increased colorectal cancer risk in this analysis.
But here comes the reveal: C-terminal somatic mutations in tumors still looked pathogenic. Why would the same region seem quiet in inherited form but suspicious in tumor form? The authors suggest tumor context may supply accomplices. Somatic C-terminal RNF43 mutations may need backup from other Wnt-pathway changes, including ZNRF3 and a proposed new driver, SFRP4.
In detective terms: the C-terminal variant alone may be a guy with a crowbar. Add the wrong neighborhood, a getaway car, and two friends named ZNRF3 and SFRP4, and suddenly we have a burglary.
Why This Case Matters
This paper does not say RNF43 is irrelevant. It says RNF43 is more subtle than the wanted poster suggested.
That has real-world weight. If someone gets a genetic test and RNF43 appears, clinicians need to know whether that result means aggressive surveillance, family cascade testing, a shrug with follow-up, or a long conversation with a genetics professional and an unusually patient coffee mug.
Recent work has been circling the same issue. A 2025 study of families with RNF43 pathogenic variants found that penetrance may be lower than expected, and some carriers had no serrated polyps or colorectal cancer. Another 2025 study reported low diagnostic yield from broad genetic testing in serrated polyposis syndrome. Meanwhile, organoid studies show that RNF43-mutant colorectal cancers can depend on Wnt and R-spondin signals, hinting at possible therapeutic vulnerabilities.
Put together, the case file says: RNF43 is a real colorectal cancer predisposition gene, but not every RNF43 mutation deserves the same mugshot.
The Verdict, For Now
The clean takeaway is wonderfully inconvenient: inherited and tumor-acquired RNF43 mutations are not interchangeable. Germline RNF43 risk seems moderate, often lacks the expected polyposis pattern, and may depend heavily on where the mutation sits. Tumor RNF43 mutations, meanwhile, may become dangerous through teamwork with other Wnt-pathway alterations.
That is less like a single villain and more like an ensemble cast of cellular misbehavior. Annoying for simple explanations. Excellent for better medicine.
If these findings hold up, RNF43 testing could become more precise: less overcalling, fewer unnecessary alarms, sharper counseling for families, and better clues about which tumors are truly leaning on Wnt signaling. The detective work is not over, but the fingerprints are getting clearer.
References
-
Palles C, Freeman-Mills L, Arbe-Barnes E, et al. Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis. Gut. 2025. DOI: https://doi.org/10.1136/gutjnl-2025-337030
-
Germline pathogenic variants in RNF43 in patients with and without serrated polyps. Familial Cancer. 2025. DOI: https://doi.org/10.1007/s10689-024-00428-6
-
Yamamoto D, Oshima H, Wang D, et al. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer. Journal of Pathology. 2022;257:39-52. DOI: https://doi.org/10.1002/path.5868. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC9314865/
-
Upadhye I, Al Maliki H, Cuthill V, Latchford A, Monahan K. Low Yield of Genetic Testing in Serrated Polyposis Syndrome. Clinical and Translational Gastroenterology. 2025;16:e00923. DOI: https://doi.org/10.14309/ctg.0000000000000923
-
Yamada A, Kondo T. Hereditary Colorectal Cancer: Clinical Implications of Genomic Medicine and Precision Oncology. Journal of the Anus, Rectum and Colon. 2025;9:167-178. DOI: https://doi.org/10.23922/jarc.2025-001
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.